Aniche (FR)
{name}
{subtitle}
Study of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-641/KEYNOTE-641)
city
~16 mi. (Valenciennes, France, +226 more cities)
facility
Centre Hospitalier de Valenciennes ( Site 0439)
condition
Prostate Adenocarcinoma
drug
enzalutamide, +1 more drug
drug type
hormone therapy, +1 more type
Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012)
city
~16 mi. (Valenciennes, France, +158 more cities)
facility
Clinique Teissier Groupe ( Site 0808)
condition
Non-Small Cell Lung Carcinoma
drug
olaparib, +4 more drugs
drug type
chemotherapy, +3 more types
Safety and Efficacy of Pembrolizumab (MK-3475) Versus Placebo as Adjuvant Therapy in Participants With Hepatocellular Carcinoma (HCC) and Complete Radiological Response After Surgical Resection or Local Ablation (MK-3475-937 / KEYNOTE-937)
city
~24 mi. (Bruyelle, Belgium, +199 more cities)
facility
Erasme Hospital ( Site 0376)
condition
Hepatocellular Carcinoma
drug
pembrolizumab
drug type
immunotherapy
Perioperative Pembrolizumab (MK-3475) Plus Cystectomy or Perioperative Pembrolizumab Plus Enfortumab Vedotin Plus Cystectomy Versus Cystectomy Alone in Cisplatin-ineligible Participants With Muscle-invasive Bladder Cancer (MK-3475-905/KEYNOTE-905/EV-303)
city
~24 mi. (Bruyelle, Belgium, +163 more cities)
facility
UCL Saint-Luc - Oncologie Medicale ( Site 0357)
condition
Bladder Urothelial Carcinoma
drug
cystectomy, +2 more drugs
drug type
chemotherapy, +3 more types
Perioperative Enfortumab Vedotin (EV) Plus Pembrolizumab (MK-3475) Versus Neoadjuvant Chemotherapy for Cisplatin-eligible Muscle Invasive Bladder Cancer (MIBC) (MK-3475-B15/ KEYNOTE-B15 / EV-304)
city
~30 mi. (Lille, France, +93 more cities)
facility
Polyclinique du Bois ( Site 0458)
condition
Bladder Carcinoma, +1 more condition
drug
cisplatin, +4 more drugs
drug type
chemotherapy, +3 more types
Study of Pembrolizumab (MK-3475) Versus Placebo in Combination With Neoadjuvant Chemotherapy & Adjuvant Endocrine Therapy in the Treatment of Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK-3475-756/KEYNOTE-756)
city
~30 mi. (Lille, France, +207 more cities)
facility
Centre Oscar Lambret ( Site 0911)
biomarker
ER Positive, +1 more biomarker
condition
Breast Invasive Ductal Carcinoma
drug
cyclophosphamide, +6 more drugs
drug type
chemotherapy, +3 more types
Pembrolizumab (MK-3475) Versus Placebo Following Surgery and Radiation in Participants With Locally Advanced Cutaneous Squamous Cell Carcinoma (MK-3475-630/KEYNOTE-630)
city
~30 mi. (Lille, France, +137 more cities)
facility
CHRU de Lille - Hopital Claude Huriez ( Site 0355)
condition
Skin Squamous Cell Carcinoma
drug
pembrolizumab
drug type
immunotherapy
Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndrome
city
~30 mi. (Lille, France, +201 more cities)
facility
CHRU Lille - Hopital Claude Huriez /ID# 220991
condition
Myelodysplastic Syndromes
drug
azacitidine, +1 more drug
drug type
chemotherapy
A Study Evaluating Safety and Efficacy of Venetoclax in Combination With Azacitidine Versus Standard of Care After Allogeneic Stem Cell Transplantation (SCT) in Participants With Acute Myeloid Leukemia (AML)
city
~30 mi. (Lille, France, +127 more cities)
facility
CHRU Lille - Hopital Claude Huriez /ID# 217916
condition
Acute Myeloid Leukemia
drug
azacitidine, +2 more drugs
drug type
chemotherapy